In conclusion, our study demonstrates for the first time, that CS1 can be used as a target antigen in a DNA vaccine to successfully induce specific cytotoxic T cell responses against myeloma cells and suppress tumor growth in vivo. This evidence concerns the gene SLAMF7 and plasma cell myeloma.